ADRC CONSORTIUM FOR CLARITY IN ADRD RESEARCH THROUGH IMAGING - PROJECT SUMMARY ALZHEIMER’S DISEASE (AD) PATHOPHYSIOLOGY SELDOM OCCURS IN ISOLATION, AND IT IS WIDELY ESTABLISHED FROM THE NEUROPATHOLOGY LITERATURE THAT THE MAJORITY OF INDIVIDUALS WITH DEMENTIA HAVE MULTIPLE ETIOLOGY DEMENTIA (MED). MED IS COMMON BUT UNDETECTED IN EXTANT MAJOR COHORT STUDIES AND TREATMENT TRIALS FOR AD; MANY STUDIES INTENTIONALLY RESTRICT CLINICAL HETEROGENEITY TO AN ASSUMED SINGLE ETIOLOGY BY USING NARROWLY DEFINED CLINICAL ENROLLMENT CRITERIA. A MAJOR GAP IN OUR FIELD IS THE LACK OF VALIDATED TOOLS TO DETECT MED IN-VIVO. THE NEXT ERA OF LARGE-SCALE IMAGING BIOMARKER STUDIES FOR AD AND RELATED DISORDERS (ADRD) WILL REQUIRE STRATEGIES COMMENSURATE WITH THE KNOWN BUT LARGELY UNADDRESSED PROBLEM OF ETIOLOGIC HETEROGENEITY. THE ALZHEIMER’S DISEASE RESEARCH CENTERS (ADRCS) ARE UNIQUELY POSITIONED TO MEET THIS NEED. COLLECTIVELY THE 37 ADRCS FOLLOW ~14,000 ACTIVE ENROLLEES WITH HIGH BRAIN DONOR AND AUTOPSY RAT

Summary

ADRC CONSORTIUM FOR CLARITY IN ADRD RESEARCH THROUGH IMAGING - PROJECT SUMMARY ALZHEIMER’S DISEASE (AD) PATHOPHYSIOLOGY SELDOM OCCURS IN ISOLATION, AND IT IS WIDELY ESTABLISHED FROM THE NEUROPATHOLOGY LITERATURE THAT THE MAJORITY OF INDIVIDUALS WITH DEMENTIA HAVE MULTIPLE ETIOLOGY DEMENTIA (MED). MED IS COMMON BUT UNDETECTED IN EXTANT MAJOR COHORT STUDIES AND TREATMENT TRIALS FOR AD; MANY STUDIES INTENTIONALLY RESTRICT CLINICAL HETEROGENEITY TO AN ASSUMED SINGLE ETIOLOGY BY USING NARROWLY DEFINED CLINICAL ENROLLMENT CRITERIA. A MAJOR GAP IN OUR FIELD IS THE LACK OF VALIDATED TOOLS TO DETECT MED IN-VIVO. THE NEXT ERA OF LARGE-SCALE IMAGING BIOMARKER STUDIES FOR AD AND RELATED DISORDERS (ADRD) WILL REQUIRE STRATEGIES COMMENSURATE WITH THE KNOWN BUT LARGELY UNADDRESSED PROBLEM OF ETIOLOGIC HETEROGENEITY. THE ALZHEIMER’S DISEASE RESEARCH CENTERS (ADRCS) ARE UNIQUELY POSITIONED TO MEET THIS NEED. COLLECTIVELY THE 37 ADRCS FOLLOW ~14,000 ACTIVE ENROLLEES WITH HIGH BRAIN DONOR AND AUTOPSY RAT